Biocept [BIOC] vs Danaher [DHR] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 21 vital metrics comparison: Biocept Inc wins in 5 metrics, Danaher Corporation wins in 11 metrics, with 1 ties. Danaher Corporation appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biocept Inc | Danaher Corporation | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.01 | 34.61 | Danaher Corporation |
| Price-to-Book Ratio | 1.55 | 2.40 | Biocept Inc |
| Debt-to-Equity Ratio | 39.97 | 37.17 | Danaher Corporation |
| PEG Ratio | 0.00 | 3.84 | Tie |
| EV/EBITDA | -0.01 | 17.69 | Danaher Corporation |
| Profit Margin (TTM) | -9.99% | 14.89% | Danaher Corporation |
| Operating Margin (TTM) | -123.69% | 22.94% | Danaher Corporation |
| EBITDA Margin (TTM) | N/A | 22.94% | N/A |
| Return on Equity | -362.16% | 7.08% | Danaher Corporation |
| Return on Assets (TTM) | -103.93% | 4.19% | Danaher Corporation |
| Free Cash Flow (TTM) | $-14.10M | $5.26B | Danaher Corporation |
| Dividend Yield | N/A | 0.56% | N/A |
| 1-Year Return | 0.00% | -10.25% | Biocept Inc |
| Price-to-Sales Ratio (TTM) | 0.04 | 5.10 | Biocept Inc |
| Enterprise Value | $354,060 | $140.38B | Danaher Corporation |
| EV/Revenue Ratio | 0.01 | 5.67 | Biocept Inc |
| Gross Profit Margin (TTM) | -332.94% | 60.34% | Danaher Corporation |
| Revenue per Share (TTM) | $46 | $35 | Biocept Inc |
| Earnings per Share (Diluted) | $-56.70 | $5.16 | Danaher Corporation |
| Beta (Stock Volatility) | N/A | 0.99 | N/A |
| Short % of Float | N/A | 1.10% | N/A |
Biocept Inc vs Danaher Corporation Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biocept Inc | 769.80% | N/A | N/A | N/A | N/A | N/A |
| Danaher Corporation | 0.56% | -1.32% | 11.85% | -5.38% | -20.75% | -21.40% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biocept Inc | 0.00% | 0.00% | 0.00% | -100.00% | -90.75% | -90.23% |
| Danaher Corporation | -10.25% | -15.98% | -20.94% | 174.08% | 416.93% | 738.84% |
Performance & Financial Health Analysis: Biocept Inc vs Danaher Corporation
| Metric | BIOC | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $1.14M | $126.39B |
| Market Cap Category | Micro cap | Large cap |
| 10 Day Avg. Volume | 402,716 | 5,174,666 |
| 90 Day Avg. Volume | 205,809 | 4,357,215 |
| Last Close | $0.43 | $181.10 |
| 52 Week Range | $0.00 - $0.49 | $160.93 - $242.80 |
| % from 52W High | -11.26% | -25.41% |
| All-Time High | $270,540.00 (Feb 03, 2014) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -100.00% | -38.83% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.12% | 0.04% |
| Quarterly Earnings Growth | N/A | 0.08% |
| Financial Health | ||
| Profit Margin (TTM) | -0.10% | 0.15% |
| Operating Margin (TTM) | -1.24% | 0.23% |
| Return on Equity (TTM) | -3.62% | 0.07% |
| Debt to Equity (MRQ) | 39.97 | 37.17 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.28 | $74.32 |
| Cash per Share (MRQ) | $6.40 | $8.06 |
| Operating Cash Flow (TTM) | $-13,221,000 | $6.44B |
| Levered Free Cash Flow (TTM) | $-32,087,000 | $4.57B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.56% |
| Last 12-Month Dividend | N/A | $1.28 |
Valuation & Enterprise Metrics Analysis: Biocept Inc vs Danaher Corporation
| Metric | BIOC (Apr 30, 2025) | DHR (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.01 | 34.61 |
| Forward P/E | -0.32 | 19.64 |
| PEG Ratio | 0.00 | 3.84 |
| Price to Sales (TTM) | 0.04 | 5.10 |
| Price to Book (MRQ) | 1.55 | 2.40 |
| Market Capitalization | ||
| Market Capitalization | $1.14M | $126.39B |
| Enterprise Value | $354,060 | $140.38B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.01 | 5.67 |
| Enterprise to EBITDA | -0.01 | 17.69 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.99 |
| Book Value per Share (MRQ) | $0.28 | $74.32 |
Financial Statements Comparison: Biocept Inc vs Danaher Corporation
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | BIOC (2022) | DHR (2025) |
|---|---|---|
| Revenue/Sales | 25.86M | 24.57B |
| Cost of Goods Sold | 28.44M | 10.05B |
| COGS % of Revenue | 110.0% | 40.9% |
| Gross Profit | -2.58M | 14.52B |
| Gross Margin | -10.0% | 59.1% |
| Research & Development | 6.16M | 1.60B |
| Operating Income (EBIT) | -31.98M | 4.69B |
| Operating Margin | -123.7% | 19.1% |
| EBITDA | -31.98M | 7.17B |
| EBITDA Margin | -123.7% | 29.2% |
| Pre-Tax Income | -32.21M | 4.23B |
| Pre-Tax Income % of Revenue | -124.6% | 17.2% |
| Income Tax | -125,000 | 633.00M |
| Income Tax % of Revenue | -0.5% | 2.6% |
| Net Income (Profit) | -32.09M | 3.61B |
| Profit Margin | -124.1% | 14.7% |
Balance Sheet & Liquidity Metrics
| Metric | BIOC (2022) | DHR (2025) |
|---|---|---|
| Cash & Equivalents | 12.90M | 4.62B |
| Total Current Assets | 16.34M | 12.76B |
| Total Current Assets % of Revenue | 63.2% | 51.9% |
| Total Current Liabilities | 5.51M | 6.81B |
| Total Current Liabilities % of Revenue | 21.3% | 27.7% |
| Long-Term Debt | 10.38M | 19.50B |
| Long-Term Debt % of Revenue | 40.1% | 79.4% |
| Total Shareholders Equity | 8.86M | 52.54B |
| Retained Earnings | -298.44M | 46.89B |
| Retained Earnings % of Revenue | -1,154.1% | 190.9% |
| Property, Plant & Equipment | 14.14M | 2.14B |
Cash Flow Statement Comparison
| Metric | BIOC (2022) | DHR (2025) |
|---|---|---|
| Operating Cash Flow | -13.22M | 5.64B |
| Operating Cash Flow % of Revenue | -51.1% | 23.0% |
| Capital Expenditures | -807,000 | -1.12B |
| Free Cash Flow | -14.10M | 5.26B |
| FCF Margin | -54.5% | 21.4% |
| Debt Repayment | -1.31M | -500.00M |
| Common Stock Repurchase | N/A | -3.09B |
Short Interest & Institutional Ownership Analysis
| Metric | BIOC | DHR |
|---|---|---|
| Shares Short | N/A | 6.94M |
| Short Ratio | N/A | 1.68 |
| Short % of Float | N/A | 1.10% |
| Shares Outstanding | 2.63M | 707.70M |
| Float Shares | N/A | 630.65M |
| % Held by Insiders | N/A | 10.78% |
| % Held by Institutions | N/A | 85.08% |
| % Held by Public | N/A | 4.14% |
Dividend Analysis & Yield Comparison: Biocept Inc vs Danaher Corporation
| Metric | BIOC | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.28 |
| Last 12-Month Dividend Yield | N/A | 0.56% |
| 3-Year Avg Annual Dividend | N/A | $10.51 |
| 3-Year Avg Dividend Yield | N/A | 1.11% |
| 3-Year Total Dividends | N/A | $31.54 |
| Ex-Dividend Date | N/A | Dec 26, 2025 |